Increased levels of circulating endothelial progenitor cells in patients with ischaemic stroke treated with statins during acute phase
European Journal of Neurology, 06/04/2012
Sobrino T et al. - Statin treatment for 4 days may increase circulating Endothelial progenitor cells (EPCs) levels, probably by NO-related mechanisms.
The authors studied 48 patients with a first-ever non-lacunar ischaemic stroke (<12 h from stroke onset).
Sixteen patients received statin treatment (20 mg atorvastatin/day) during the first 4 days.
The authors defined the EPC increment during the first week as the difference in the number of early outgrowth colony-forming unit–endothelial cell (CFU-EC) between day 7 and at admission (previous to atorvastatin treatment).
Serum levels of vascular endothelial growth factor (VEGF) and active MMP-9 (determined by ELISA), and nitric oxide metabolites (NOx) (determined by HPLC) were measured at admission, 24 and 72 h, and day 7.
Colony-forming unit–endothelial cell were similar at baseline between patients treated (n = 16) and non-treated (n = 32) with statins (10.1 ± 3.9 vs. 7.9 ± 6.9 CFU-EC, P = 0.223).
However, patients treated with statins showed a higher EPC increment (24.0 ± 17.3 vs. 6.0 ± 17.8 CFU-EC, P = 0.002) during the first week.
An EPC increment ≥4 CFU-EC predicted with the highest sensitivity (88%) and specificity (92%) the probability of good outcome (area under the curve 0.903, P < 0.0001).
Statin treatment (OR, 13.1; CI 95%, 2.2–76.9, P = 0.004) was independently associated with an EPC increment ≥ 4 CFU-EC after adjustment for confounder factors, but this association was lost when adjusting for NOx levels.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.